This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
I don’t do advertising on my blog, but I thought it was worth mentioning Ryan in particular because he has an alternate model for doing a startup. Pricing engine helps publishers ascertain ad inventory pricing by analyzing ad transaction data from the market/exchanges. They sponsor TWiVC. MetaMarkets. Hello, Chair.
An investment doesn’t guarantee your product will suddenly be on the investor’s price sheet. Diverse search results include stream updates, blog posts, news articles, photos, videos (versus Twitter/FaceBook1 only). Current round: $5.0mm in Series A by NEA and Anthem Venture Partners. Real-time search engine.
One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of the drug, nusinersen (Spinraza), might make it hard for some with the disease to get treatment.
health insurer, UnitedHealthCare, has said it would cover the first-ever approved drug for the rare disease spinal muscular atrophy, a closely watched bellwether in the national debate over drug prices. Another major U.S.
But just after Christmas, she saw the price. More than a decade after his diagnosis, Mikhail only has the strength to take a few steps on his own. With the approval, Memedovich finally had hope. Cambridge, MA-based Biogen (NASDAQ: BIIB ), the drug’s. Read more » Reprints | Share:
At the same time, a handful of the industry’s top CEO’s flew to Washington for a meeting with the President, who promised to speed the drug approval process, lower drug prices, and overhaul the FDA. Meanwhile, the future of the Affordable Care Act remains undecided, and Tom Price’s controversial candidacy for the top healthcare.
Melissa Marotta pulled no punches to get her three-year-old son C.J., who has the genetic disease spinal muscular atrophy, access to nusinersen (Spinraza), the first approved drug for his condition.
It was a wild week in biotech and on Capitol Hill. A new study showed it may take another 40 years to achieve gender diversity in life sciences. Tensions continued to mount between drugmakers and payers over the rising costs of rare disease drugs.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content